Women with preterm premature rupture of the membranes do not benefit from weekly progesterone.
Am J Obstet Gynecol
; 204(1): 54.e1-5, 2011 Jan.
Article
in En
| MEDLINE
| ID: mdl-20869038
ABSTRACT
OBJECTIVE:
We sought to determine if 17-alpha-hydroxyprogesterone (17P) extends gestation vs placebo in women with preterm premature rupture of the membranes (PPROM). STUDYDESIGN:
Women with vertex presentations with PPROM, 20-30 weeks' gestation, were randomized to receive weekly 17P or placebo in an attempt to prolong the pregnancy. A total of 69 patients (17P, n = 33; placebo, n = 36) were randomized into this study.RESULTS:
Initial cervical dilatation, gestational age at enrollment, and interval to delivery were not different between the 2 groups (P = .914, .424, and .146, respectively). Time of randomization to delivery (P = .250), mode of delivery (relative risk, 1.16; 95% confidence interval, 0.66-2.06), and the neonatal outcome statistics of morbidity (P = .820) and mortality (relative risk, 1.28; 95% confidence interval, 0.59-2.75) were similar between the 2 groups.CONCLUSION:
In patients with PPROM, 17P did not extend gestation vs placebo and cannot be recommended for treatment in such women.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Fetal Membranes, Premature Rupture
/
17-alpha-Hydroxyprogesterone
/
Premature Birth
Type of study:
Clinical_trials
/
Etiology_studies
Limits:
Adult
/
Female
/
Humans
/
Pregnancy
Country/Region as subject:
America do norte
Language:
En
Journal:
Am J Obstet Gynecol
Year:
2011
Document type:
Article
Affiliation country:
United States